DrugBiological
Ofatumumab clinical trials
Also written Arzerra, HuMax-CD20, GSK1841157 and OMB157.
- studies test it
- 105
- open now
- 2
- in phase 3
- 16
- first study started
- 2004
Keep track of what changes. Save the ofatumumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
104 studies that test it; most in 2011 (24)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2006 | 1 |
| 2007 | 4 |
| 2008 | 6 |
| 2009 | 4 |
| 2010 | 19 |
| 2011 | 24 |
| 2012 | 11 |
| 2013 | 6 |
| 2014 | 2 |
| 2015 | 6 |
| 2016 | 4 |
| 2018 | 2 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 4 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 76
- Phase 3
- 16
- Phase 4
- 7
What it is tested for
Each study’s main condition, where its own words name it.
- Lymphoma
- 10
Who runs them
Industry 44 · Other 61
Novartis Pharmaceuticals (22) · GlaxoSmithKline (20) · M.D. Anderson Cancer Center (8) · H. Lee Moffitt Cancer Center and Research Institute (3) · Gruppo Italiano Malattie EMatologiche dell'Adulto (3) · SCRI Development Innovations, LLC (3) · Dana-Farber Cancer Institute (2) · Sidney Kimmel Cancer Center at Thomas Jefferson University (2)
Often tested with
Tested in the same studies.
Bendamustine (12) · Lenalidomide (5) · Ibrutinib (4) · Cyclophosphamide (4) · Methylprednisolone (3) · Pentostatin (3) · Bortezomib (3) · Alemtuzumab (2)
Studies
Open first, then newest update. How each study uses ofatumumab is read from its arms, and is right about nine times in ten.
Testing it · 105
- Ofatumumab in Treatment-Refractory¬ Narcolepsy Type 1RecruitingPhase 1/2Xijing HospitalNCT07871006Written as ofatumumab 20mg
- Ofatumumab in AQP4-IgG Seropositive NMOSDRecruitingPhase 1/2Tang-Du HospitalNCT05504694Written as Ofatumumab
- A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) ElevationActive, not recruitingPhase 4Novartis PharmaceuticalsNCT05090371Written as Ofatumumab
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MSActive, not recruitingPhase 3Novartis PharmaceuticalsNCT03650114Written as Ofatumumab
- Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple SclerosisActive, not recruitingPhase 3Novartis PharmaceuticalsNCT04926818Written as Ofatumumab
- An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to OfatumumabCompletedPhase 3Novartis PharmaceuticalsNCT04353492Written as Ofatumumab
- A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLLCompletedPhase 2Dana-Farber Cancer InstituteNCT02135133Written as Ofatumumab
- Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMSCompletedPhase 3Novartis PharmaceuticalsNCT04788615Written as Ofatumumab
- Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.CompletedPhase 4Novartis PharmaceuticalsNCT05084638Written as Ofatumumab
- 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple SclerosisCompletedPhase 3Brigham and Women's HospitalNCT04510220Written as Ofatumumab
- A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple SclerosisCompletedPhase 3Novartis PharmaceuticalsNCT04486716Written as Ofatumumab
- Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in ChinaCompletedPhase 4Novartis PharmaceuticalsNCT05199571Written as Ofatumumab
- Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLLCompletedPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT01496976Written as Ofatumumab
- Ofatumumab for Minimal Residual Disease (MRD) and Maintenance TherapyTerminatedPhase 2M.D. Anderson Cancer CenterNCT01258933Written as Ofatumumab
- Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic LeukemiaActive, not recruitingPhase 2Northwestern UniversityNCT01361711Written as ofatumumab
- Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With OfatumumabCompletedPhase 4Novartis PharmaceuticalsNCT04869358Written as Ofatumumab
- A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With OfatumumabTerminatedPhase 4Novartis PharmaceuticalsNCT04878211Written as Ofatumumab
- Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and EtoposideCompletedPhase 1/2Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT01458366Written as Ofatumumab
- Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and LymphomaTerminatedPhase 1Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT01352312Written as Ofatumumab
- Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell TransplantCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT01437709Written as Ofatumumab (This arm is closed)
See all 105 studies that test ofatumumab →
Given in every arm · 10 — ofatumumab is usual care beside what is tested
- Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT03136146Written as Ofatumumab
- Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT02877303Written as Ofatumumab
- An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).Not yet recruitingEarly Phase 1The Affiliated Hospital of Xuzhou Medical UniversityNCT07546110Written as ofatumumab
- Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic LeukemiaTerminatedPhase 2M.D. Anderson Cancer CenterNCT03488225Written as Ofatumumab
- Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin LymphomaCompletedPhase 2National Cancer Institute (NCI)NCT01286272Written as Ofatumumab
- Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLLCompletedPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT01145209Written as Ofatumumab
- Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic LeukemiaCompletedPhase 1Gilead SciencesNCT01088048Written as Ofatumumab
- Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to RituxtherapyTerminatedPhase 3Novartis PharmaceuticalsNCT01077518Written as Ofatumumab
- Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic LeukemiaTerminatedPhase 3Gilead SciencesNCT01659021Written as Ofatumumab
- A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive TreatmentStatus unknownPhase 3University of LiverpoolNCT01678430Written as Ofatumumab
As the comparator · 5 — what is tested is compared with ofatumumab
- Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune EncephalitisRecruitingPhase 3The First People's Hospital of ChangzhouNCT06867991Written as Ofatumumab
- A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)CompletedPhase 3SecuraBioNCT02004522Written as Ofatumumab
- A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07CompletedPhase 3SecuraBioNCT02049515Written as Ofatumumab
- A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedPhase 3Pharmacyclics LLC.NCT01578707Written as ofatumumab
- A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)CompletedPhase 3Merck Sharp & Dohme LLCNCT01580228Written as Ofatumumab
Codes
What other systems call ofatumumab · ClinicalTrials.gg INT005243
- MeSH (NLM) C527517ofatumumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) M95KG522R0OFATUMUMABConfirmed FDA, NLM, Wikidata
- RxNorm 712566Confirmed FDA, Wikidata
- Wikidata Q410656ofatumumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66952OfatumumabConfirmed FDA, Wikidata
- DrugBank DB06650One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C527517 | ofatumumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | M95KG522R0 | OFATUMUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 712566 | — | Confirmed FDA, Wikidata |
| Wikidata | Q410656 | ofatumumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66952 | Ofatumumab | Confirmed FDA, Wikidata |
| DrugBank | DB06650 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.